Xhale's Smart Technology Showcased at Drug Development Meeting

GAINESVILLE, Fla. - June 10, 2014 - PRLog -- Xhale Smart, Inc., developer of the SMART® Medication Adherence System, today announced that the company has been invited to present the SMART® System at three key meetings during the month of June.  The SMART® presentations include:

"Usability Evaluation of SMART® Adherence System in HIV/AIDS Patients" Poster, 9th International Conference on HIV Treatment and Prevention Adherence, Miami, FL, June 8 - 10, 2014

“SMART®: A Breath-Based Technology to Definitively Document Adherence to Medications” Presentation, Innovation Showcase: Advanced Drug Delivery Approaches for Small and Large Molecules, Catalent Applied Drug Delivery Institute, St. Paul, MN, June 12, 2014

"Definitive Verification and Monitoring of Oral Medication Adherence Using Breath Analysis" Poster, American Society of Clinical Psychopharmacology (ASCP) 54^th Annual Meeting, Hollywood, FL, June 16 - 19, 2014, Nominated for Best Poster

Previous meetings of these professional groups have highlighted the widespread problem of study participants not taking study medications as directed and its adverse impact on clinical trials and drug development programs. Xhale's presentations demonstrate the potential of the SMART® System to address the significant need for a reliable adherence tracking tool that can verify, monitor, and report medication adherence.

The SMART® Medication Adherence System is designed to offer definitive and noninvasive monitoring of medication adherence, utilizing exhaled breath to confirm that medication has been taken by study participants as directed. Through near real-time reporting of reliable adherence information and a user-friendly breath analysis device, the SMART® System offers significant potential to improve clinical trial execution and outcomes.

About Xhale, Inc., Xhale Smart, Inc. and  Xhale Assurance, Inc.

Xhale, Inc. is a medical technology company developing and commercializing patient-centric monitoring solutions for the healthcare industry. Xhale, Inc. is focused on developing two broad technology platforms. Through its Xhale Smart, Inc. subsidiary, Xhale, Inc. is developing a medication adherence monitoring technology designed to verify, monitor, report, and improve adherence to medication regimens in clinical trials. The SMART® Adherence System is the only technology that offers definitive and noninvasive monitoring of medication adherence in near real-time, utilizing exhaled breath to confirm that medication has been taken as directed. Xhale Smart is an emerging leader in patient-centric monitoring solutions for medication adherence. Through its Xhale Assurance, Inc. subsidiary, Xhale, Inc. is developing a patient monitoring technology designed to improve and expand the use of conventional pulse oximetry used in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured. Xhale, Inc.’s first product based on this technology, the Assurance® Alar One-Sense™ pulse oximetry sensor, received marketing clearance in the United States. The Assurance® Alar One-Sense™ pulse oximetry sensor is a disposable sensor placed on a patient’s nasal ala which transmits heart rate and blood oxygenation information to an oximetry monitor.

For more information, please visit http://www.xhale.com or contact the company at info@xhale.com or 352-371-8488.